Outstanding Scientific Achievement Award lecturer highlights evolution of unimolecular therapies

A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism

Biased Dual-Agonists of GLP-1 and Glucagon Receptors Developed Through Conserved Aspartate Mutation

This article describes a scientific discovery where researchers engineered biased dual-agonists of the glucagon-like peptide 1 receptor (GLP

ADA 2026 Scientific Sessions: New GLP-1 Drugs and Diabetes Research Highlights

In this JAMA Medical News podcast, Jennifer Abbasi interviews Dr. Rita Kalyani, the ADA's Chief Scientific and Medical Officer, about key hi

Global protein-ligand binding affinity profiling via photocatalytic labeling

Guest Essay: Serendipitous Science Like the Gila Monster Discovery That Led to GLP-1 Drugs Is Under Threat

A guest essay argues that funding for "weird" or serendipitous scientific research is under threat, using the example of John Eng's 1990s di

Guest Essay: Serendipitous Science Like the Gila Monster Discovery That Led to GLP-1 Drugs Is Under Threat

A guest essay argues that funding for "weird" or serendipitous scientific research is under threat, using the example of John Eng's 1990s di

Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development

The article reveals previously untold history about early GLP-1 drug development in the late 1980s and early 1990s. The author was part of w